在败血症中,基于转录组的风险模型使得预后预测和药物重新定位成为可能
Qiuyue Long1,2, Hongli Ye1,2, Shixu Song1,2
1Department of Respiratory, Critical Care and Sleep Medicine, Xiang'an Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen 361101, China.
iScience
|December 4, 2024
概括
这项研究开发了一种新的风险评分模型,使用四个用于早期败血症分层的基因. 该模型准确诊断败血症并预测结果,确定改善患者管理的潜在治疗目标.
科学领域:
- 生物医学科学 生物医学科学
- 基因组学就是基因组学.
- 免疫学 免疫学 免疫学
背景情况:
- 由于宿主免疫反应的多样性,败血症的管理具有挑战性.
- 败血症患者的早期分层对于有效治疗至关重要.
研究的目的:
- 开发一种风险模型,用于早期的败血症分层,使用转录基因签名.
- 根据不同的转录形状,识别出新的败血症治疗药物.
主要方法:
- 组合了四个基因 (OLAH,LY96,HPGD,ABLIM1) 成为一个预后风险评分模型.
- 利用转录组数据进行败血症诊断和预后评估.
- 进行单细胞转录组分析以阐明免疫细胞中的基因表达模式.
- 在败血症小鼠模型中评估已识别的治疗剂.
主要成果:
- 风险评分模型在败血症诊断 (AUC=0.99-1.00) 和预后 (AUC=0.61-0.70) 中显示出高准确度.
- 该模型在高风险患者中确定了免疫抑制状态,在低风险患者中确定了低皮素反应.
- 雷丁胺和洛西卡姆在败血症小鼠模型中显著改善了生存率.
结论:
- 开发的风险模型为败血症管理提供了优化的风险分层.
- 该研究通过药物重新定位确定了毒的潜在治疗剂.
- 这种方法为败血症管理和治疗提供了一个全面的战略.
相关概念视频
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).


